The effects of acarbose treatment on intimal hyperplasia in a rat carotid endarterectomy model of diet-induced insulin resistance

Vascular and Endovascular Surgery

Volumn 44, Issue 7, 2010, Pages 560-567

  Nyalala, John O ^a   Shaoke Luo, ^a   Campbell, Danielle N ^a   Brown, Aliza T ^a   Moursi, Mohammed M ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

acarbose; blood flow velocities; carotid endarterectomy; insulin resistance; intimal hyperplasia; rat

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD FLOW VELOCITY; CARBOHYDRATE INTAKE; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NONHUMAN; RAT;

ACARBOSE; ANIMALS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; CAROTID ARTERIES; CAROTID STENOSIS; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; ENDARTERECTOMY, CAROTID; HYPERPLASIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; TIME FACTORS; TUNICA INTIMA; ULTRASONOGRAPHY, DOPPLER, PULSED;

EID: 77956931326     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574410377019     Document Type: Article

References (38)

1. Sdringola S., Assali A., Anderson H., Smalling RW Restenosis: relationship with thrombosis. Curr Intern Cardiol Rep. 2000 ; 2 (4). 285-292.
2. Jawien A., Bowen-Pope D., Lindner V., Schwartz SM, Clowes AW Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992 ; 89 (2). 507-511.
3. Berceli SA, Jiang Z., Klingman NV, et al. Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling. J Vasc Surg. 2004 ; 39 (5). 1084-1090.
4. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation. 1999 ; 100 (25). 2477-2484.
5. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004 ; 94 (10). 1249-1254.
6. Kornowski R., Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation. 1997 ; 95 (6). 1366-1369.
7. Yamagishi S., Imaizumi T. Diabetic Vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005 ; 11 (18). 2279-2299.
8. Piatti P., Mario C., Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003 ; 108 (17). 2074-2081.
9. Hanefeld M., Schaper F., Koehler C., et al. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. Horm Metab Res. 2009 ; 41 (2). 132-136.
10. McNamara DB, Murthy SN, Fonseca AN, Desouza CV, Kadowitz PJ, Fonseca VA Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. Can J Physiol Pharmacol. 2009 ; 87 (1). 37-50.
11. Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006 ; 107 (1). 11-20.
12. Godbout A., Chiasson JL Who should benefit from the use of alpha-glucosidase inhibitors ? Curr Diab Rep. 2007 ; 7 (5). 333-339.
13. Fischer S., Patzak A., Rietzsch H., et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab. 2003 ; 5 (1). 38-44.
14. Azuma K., Toyofuku Y., Iesaki T., et al. Acarbose, an α-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophy Res Commun. 2006 ; 345 (2). 688-693. (Pubitemid 43776986)
15. Yamagishi S., Matsui T., Ueda S., Fukami K., Okuda S. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab. 2009 ; 10 (2). 159-163.
16. Hanefeld M., Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther. 2008 ; 6 (2). 153-163.
17. Hanefeld M., Chiasson JL, Koehler C., Henkel E., Schaper F., Kurttschiev TT Acabose slows progression of intimal-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004 ; 35 (5). 1073-1078.
18. Chiasson JL, Josse RG, Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003 ; 290 (4). 486-494.
19. Yamagishi S., Nakamura K., Takeuchi M. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome. Med Hypotheses. 2005 ; 65 (1). 152-154. (Pubitemid 40704544)
20. Shimabukuro M., Higa N., Chinen I., Yamakawa K., Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006 ; 91 (3). 837-842.
21. Ridray S. Hyperinsulinemia and smooth muscle cell proliferation. Int J Obes Relat Metab Disord. 1995 ; 19 (suppl 1). S39 - S51.
22. Brown AT, Smith TP, Cruz CP, et al. Intimal hyperplasia following carotid endarterectomy in an insulin-resistant rat model. Metabolism. 2003 ; 52 (7). 834-839.
23. Southern FN, Cruz N., Fink LM, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg. 1998 ; 28 (5). 909-918.
24. Bledsoe SL, Barr JC, Fitzgerald RT, et al. Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model. Vasc Endovasc Surg. 2006 ; 40 (1). 49-57.
25. Brown AT, Chen H., Davis JA, et al. Plasma homocysteine measurements after carotid artery manipulation and clamping in a rat CEA model. J Vasc Surg. 2004 ; 40 (4). 796-803.
26. Davis JA, Brown AT, Chen H., et al. Cigarette smoke increases intimal hyperplasia and homocysteine in a rat carotid endarterectomy. J Surg Res. 2004 ; 121 (1). 69-75.
27. Cruz CP, Eidt J., Drouilhet J., et al. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg. 2001 ; 34 (4). 724-729.
28. Kalapatapu VR, Satterfield L., Brown AT, et al. The effects of Toradol on postoperative intimal hyperplasia in a rat carotid endarterectomy model: laboratory research. Vasc Endovascular Surg. 2007 ; 41 (5). 402-408.
29. Bledsoe SL, Brown AT, Davis JA, Chen H., Eidt JF, Moursi MM Effect of clopidogrel on platelet aggregation and intimal hyperplasia following carotid endarterectomy in the rat. Vascular. 2005 ; 13 (1). 43-49.
30. Balfour JA, McTavis D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993 ; 46 (6). 1025-1054.
31. Bavenholm PN, Efendic S. Postprandial hyperglycaemia and vascular damage-the benefits of acarbose. Diabetes Vasc Dis Res. 2006 ; 3 (2). 72-79.
32. Aronson D., Bloomgarden Z., Rayfield EJ Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996 ; 27 (3). 528-535.
33. Tsunosue M., Mashiko N., Ohta Y., et al. An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med. 2010 ; 10 (2). 139-141.
34. Park SH, Marso SP, Zhou Z., Foroudi F., Topol EJ, Lincoff M. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation. 2001 ; 104 (7). 815-819.
35. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med. 2006 ; 6 (3). 351-358.
36. Vallejo S., Angulo J., Peiro C., et al. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol. 2000 ; 36 (2). 256-262.
37. Ceriello A., Mercuri F., Quagliaro L., et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001 ; 44 (7). 834-838.
38. Schiekofer S., Andrassy M., Chen J., et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MARK, and nuclear factor kappaB in PBMCs. Diabetes. 2003 ; 52 (3). 621-633.